5 Gene Editing Stocks With the Best Long-Term Potential

2. Agilent Technologies, Inc. (NYSE:A)

Number of Hedge Fund Holders: 48

Agilent Technologies, Inc. (NYSE:A) makes tools for the gene editing space, including sample quality control (QC), next-generation sequencing (NGS) library prep and target enrichment, microarrays, CRISPR, PCR/qPCR, bioreagents and other solutions for data analysis and reporting.

Earlier this month, Agilent Technologies, Inc. (NYSE:A) launched Agilent SureSelect Cancer CGP (Comprehensive Genomic Profiling) Assay for somatic variant profiling for a range of solid tumors.

Out of the 943 hedge funds tracked by Insider Monkey, 48 hedge funds had stakes in Agilent Technologies, Inc. (NYSE:A) as of the end of the fourth quarter of 2022, up from 46 hedge funds in the previous quarter. The biggest stakeholder of Agilent Technologies, Inc. (NYSE:A) was Ian Simm’s Impax Asset Management which owns a $587 million stake in the company.

Cooper Investors made the following comment about Agilent Technologies, Inc. (NYSE:A) in its Q4 2022 investor letter:

“Agilent Technologies, Inc. (NYSE:A) finished a great year with +12% organic growth after a +15% year in 2021. As a supplier of liquid chromatography/ mass spectrometry instruments into the life sciences industry, Agilent enjoyed a period of super-normal growth over the 2020-2021 COVID pandemic. Like several of our healthcare and diagnostics investments Agilent de-rated quite sharply in the first half of 2022 as the market ‘faded’ the decline in COVID testing revenues. In our view this short term volatility obscures the high quality of Agilent’s business and long term growth opportunities. One example is environmental testing as mandated by the US EPA where US$4bn of funding in the infrastructure bill has been put aside for PFAS testing. As CEO Mike McMullen noted on the last call, ‘it’s the first time in my career we’ve seen this kind of government money coming in’.”